eAppendix. Study Inclusion and Exclusion Criteria Eligibility Criteria
The following criteria must be met for the patient to be enrolled in the study:
1. Age 5 to <13 years.
2. Amblyopia associated with strabismus, anisometropia, or both (previously treated or untreated).
a. Criteria for strabismus: ≥1 of the following must be met:
 Presence of a heterotropia on examination at distance or near fixation (with or without spectacles)
 Documented history of strabismus that is no longer present (which in the judgment of the investigator could have caused amblyopia) b. Criteria for anisometropia: ≥1 of the following criteria must be met:  SE must be within 0.50 D of fully correcting the anisometropia  SE must not be undercorrected by >1.50 D SE, and reduction in plus sphere must be symmetrical in the 2 eyes  Cylinder power in both eyes must be within 0.50 D of fully correcting the astigmatism  Cylinder axis must be within ±10° if cylinder power is ≤1.00 D, and within ±5° if cylinder power is >1.00 D. This criterion does not apply for dry overrefractions performed for patients with contact lens correction  Myopia must not be undercorrected by >0.25 D or overcorrected by >0.50 D SE, and any change must be symmetrical in the 2 eyes b. Refractive error correction meeting the above criteria must be worn:
 16 Weeks OR until VA stability is documented (defined as <0.1 logMAR change by the same testing method measured on 2 consecutive examinations ≥4 weeks apart)
c. For determining VA stability (nonimprovement) c :
 The first of 2 measurements may be made: (1) in current correction or (2) in trial frames with or without cycloplegia or (3) without correction (if new correction is prescribed)
 The second measurement must be made without cycloplegia in the correct spectacles that have been worn for ≥4 weeks  The same form of correction must be worn throughout the entire study (ie, no changing between contacts and spectacles). Monocular or binocular contact lens wear is allowed provided that the overrefraction with the contact lenses meets the above requirements. Safety glasses are not required for patients wearing contact lenses, but investigators are encouraged to suggest safety glasses be worn over contact lenses.
5. Visual acuity, measured in each eye without cycloplegia in current refractive correction (if applicable) within 7 days prior to randomization using the ATS-HOTV VA protocol for children <7 years and the E-ETDRS VA protocol for children ≥7 years on a study-approved device displaying single surrounded optotypes, as follows: 6. Heterotropia or heterophoria with a total near deviation of ≤10Δ (measured by PACT).
7. Ability to align the nonius cross on the binocular game system (angles of ocular deviation >10Δ would require the nonius cross to be adjusted to such an extent that playing of the game would be compromised).
8. Patient is able to play the special game on the study iPad (on the easy setting) under binocular conditions (with red-green glasses), as demonstrated by scoring ≥1 line in the office.
9. Investigator is willing to prescribe computer game play or patching per protocol.
10. Parent understands the protocol and is willing to accept randomization.
11. Parent has a telephone (or access to a telephone) and is willing to be contacted by Jaeb Center staff.
12. Relocation outside of area of an active PEDIG site for this study within the next 16 weeks is not anticipated.
Exclusion Criteria
1. Prism in the refractive correction at time of enrollment (eligible only if prism is discontinued 2 weeks prior to enrollment).
2. Myopia greater than −6.00 D SE in either eye.
3. Previous intraocular or refractive surgery.
4. Known skin reactions to patch or bandage adhesives.
5. Any treatment for amblyopia (patching, atropine, Bangerter filter, or vision therapy) during the past 2 weeks. Previous amblyopia therapy is allowed regardless of type but must be discontinued ≥2 weeks immediately prior to enrollment.
6. Ocular comorbidity that may reduce VA determined by an ocular examination performed within the past 7 months. 8. Severe developmental delay that would interfere with treatment or evaluation (in the opinion of the investigator). Patients with mild speech delay or reading and/or learning disabilities are not excluded.
9. Heterotropia or heterophoria with a total ocular deviation >10Δ (phoria plus tropia >10Δ) at near (measured by PACT). Patients with cycloplegic refractive errors that do not fall within the requirements stipulated for spectacle correction may be given spectacles at investigator discretion but must follow the studyspecified prescribing guidelines.
c Because this determination is a prestudy procedure, the method of measuring VA is not mandated. For analyses other than the primary analysis, the modification to the primary analysis is specified. Treatment group difference (Patching -Binocular Group) in mean change in amblyopic-eye visual acuity from baseline to 16 weeks, adjusted for baseline covariates of age and amblyopic-eye visual acuity. Upper limit of the 1-sided 95% confidence interval computed on the treatment group difference (Patching -Binocular Group), adjusted for baseline covariates of age and amblyopic-eye visual acuity. The upper-limit of the 1-sided 95% confidence interval for all of the analysis approaches exceeded the pre-specified non-inferiority margin of 0.5 line, consistent with the primary analysis result. Analyses were limited to participants who completed the 16-week visit within the pre-defined analysis window (14 to <20 weeks after randomization). b Four participants (1 binocular group, 3 patching group) were excluded due to unknown/not reported race/ethnicity classification. c Subgroup analyses tested the interaction of baseline factors with treatment group on VA change at 16 weeks. P-value based on the addition of an interaction term between treatment group and each factor to the primary analysis model. Baseline factors of age and amblyopic-eye visual acuity were treated as continuous variables in the regression models. All of the subgroup factors were prespecified except for baseline stereoacuity. 0  0  0  0  1  <1  0  0  Nil  29  27  13  14  23  22  13  14  2000  14  13  17  18  14  13  12  13  800  8  7  11  12  12  11  14  16  400  10  9  10  11  10  10  10  11  200  18  17  12  13  12  11  17  19  100  19  18  17  18  14  13  15  17  60  7  7  7  8  9  9  6  7  40  2  2  5  5  10  10  3  3  Median  400  400 400 400
Analysis
Results of the Randot Butterfly stereoacuity test were analyzed as 2000 seconds of arc (if correct response). Nil was defined as an incorrect response on the butterfly (n=67 and n=56 in binocular and patching groups at baseline, respectively; n=61 and n=50 in binocular and patching groups at 16 weeks, respectively), or on the 800 seconds of arc level of the Randot Preschool stereoacuity test if the butterfly was not attempted (n=2 and n=1 in binocular treatment and patching groups at baseline, respectively; n=1 and n=0 in the binocular and patching groups at 16 weeks, respectively). The Wilcoxon rank-sum test was used to compare the change in stereoacuity levels from baseline to 16 weeks by treatment group. P = 0.66 and P = 0.19 for the overall cohort and for participants without strabismus, respectively, from Wilcoxon rank-sum test for difference between treatment groups in distribution of levels of change from baseline to 16 weeks. Analyses were limited to participants who completed the 16-week visit within the predefined analysis window (14 to <20 weeks after randomization). The median level at baseline and change in stereoacuity at 16 weeks was tabulated according to the baseline subgroup factors of interest from the primary VA analysis.Baseline stereoacuity was measured as log seconds of arc as follows: 1.60 (40'), 1.78 (60'), 2.00 (100'), 2.30 (200'), 2.60 (400'), 2.90 (800'), 3.30 (2000') and 3.60 (nil). Change in stereoacuity was calculated as the difference in the log seconds of arc (baseline -16 weeks). Relationship between change in 16-week outcomes and objective compliance measures (total hours of game play, change in fellow-eye contrast from baseline) in the binocular group were evaluated using descriptive statistics and scatterplots. The scatterplots on the top row represent the relationship between the change in 16-week amblyopic-eye visual acuity (VA) from baseline and (1) cumulative hours of binocular treatment at 16 weeks (top left) and (2) change in fellow-eye contrast from baseline to 16 weeks (top right). The scatterplots on the bottom row represent the relationship between the change in 16-week stereoacuity from baseline and (1) cumulative hours of binocular treatment at 16 weeks (bottom left) and (2) change in fellow-eye contrast from baseline to 16 weeks (bottom right). Positive values for change in VA and stereoacuity indicate improvement. Analyses were limited to participants who completed the 16-week visit within the pre-defined analysis window (14 to <20 weeks after randomization). were evaluated using scatterplots. The scatterplots represent the relationship between the change in 16-week amblyopic-eye visual acuity (VA) from baseline and (1) (yes/no) were evaluated using scatterplots. The scatterplots represent the relationship between the change in 4-week stereoacuity from baseline and (1) cumulative hours of binocular treatment at 4 weeks (left column) and (2) the change in fellow-eye contrast from baseline to 4 weeks (right column). Positive values for stereoacuity change indicate improvement. Analyses were limited to participants who completed the 4-week visit within the pre-defined analysis window (3 to <6 weeks after randomization). 
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